Ocugen (OCGN) Set to Release Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $1.32 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.89 million. On average, analysts expect Ocugen to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Ocugen Stock Up 3.6%

Shares of OCGN opened at $0.79 on Wednesday. The stock has a 50-day moving average of $1.07 and a two-hundred day moving average of $1.44. Ocugen has a one year low of $0.70 and a one year high of $2.73.

Insider Activity at Ocugen

In other news, CEO Shankar Musunuri sold 57,264 shares of Ocugen stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $0.95, for a total value of $54,400.80. Following the transaction, the chief executive officer directly owned 1,030,771 shares of the company’s stock, valued at $979,232.45. The trade was a 5.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,051,982 shares of company stock valued at $1,088,801 over the last ninety days. 3.95% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings upgraded Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.